Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Download PDF Copy

Reviewed

Acceleron Pharma, Inc.May 22 2014

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that Acceleron, Celgene and investigators in the sotatercept and ACE-536 phase 2 clinical trials will give three oral presentations of interim data from ongoing studies in beta-thalassemia and myelodysplastic syndromes as well as a poster presentation of nonclinical data in sickle cell disease at the 19^th Annual Congress of the European Hematology Association (EHA) in Milan, Italy from June 12-15, 2014.

ACE-536: Beta-thalassemia Oral Presentation

ACE-536: Myelodysplastic Syndromes Oral Presentation

Sotatercept: Beta-thalassemia Oral Presentation

ACE-536: Sickle Cell Disease Poster Presentation

Source:

Acceleron Pharma, Inc.

Posted in: Medical Condition News

Tags: B Cell, Beta-Thalassemia, Biopharmaceutical, Blood, Cancer, Cell, Erythropoiesis, Erythropoietin, G-Protein, Hematology, I Cell Disease, Myelodysplastic Syndromes, Pharmaceuticals, Protein, Rare Disease, Sickle Cell Disease, T-Cell, Thalassemia, Therapeutics